EAST WINDSOR, N.J. – Aurobindo Pharma has gotten final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Application azelastine hydrochloride nasal spray 0.15% (205.5 mcg per spray). Aurobindo Pharma’s azelastine hydrochloride nasal spray 0.15% (205.5 mcg per spray) are an AB-rated generic equivalent to the reference listed drug (RLD), Astepro Nasal Spray, 0.15%, of Mylan Specialty.
Azelastine hydrochloride nasal spray is indicated for:
- the relief of the symptoms of seasonal allergic rhinitis in patients 6 years of age and older and perennial allergic rhinitis in patients 6 years of age and older.
Azelastine hydrochloride nasal spray has an estimated market size of US $15.2 Million for the twelve months ending September 2020 as per IQVIA.
Comments are closed.